Fused Heterocyclic 5-HT2A Agonists With 5-HT2B Selectivity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current 5-HT2A receptor agonists lack selectivity over the 5-HT2B receptor, leading to serious side effects such as drug-induced valvular heart disease.
Innovation Solution
Development of compounds that selectively bind to the 5-HT2A receptor over the 5-HT2B receptor, represented by specific fused heterocyclic structures and their pharmaceutically acceptable salts, for use in pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective 5-HT2A receptor agonists are used, then therapeutic effect is achieved, but serious side effects occur due to 5-HT2B receptor activation
Solution Approach 1:
The patent applies local quality by introducing a specific fused heterocyclic ring system (pyridine ring fused to the indole core) at a precise location in the molecule. This local structural modification creates a unique binding interface that selectively interacts with the 5-HT2A receptor while avoiding 5-HT2B receptor binding, thereby achieving high selectivity and eliminating harmful side effects without compromising therapeutic efficacy.
Solution Approach 2:
The patent employs parameter changes by systematically modifying molecular parameters including the introduction of a pyridine nitrogen atom, adjustment of substituent positions (R1-R8 groups), and optimization of bond angles and distances. These parameter modifications fine-tune the receptor binding affinity and selectivity, enabling discrimination between 5-HT2A and 5-HT2B receptors while maintaining therapeutic activity.
2Object-affected harmful factors
If selective 5-HT2A receptor agonists are developed, then side effects are reduced, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: the core indole unit, the fused pyridine ring system, and the variable substituent groups (R1-R8). This segmentation allows independent optimization of each segment - the core provides binding affinity while the substituents fine-tune selectivity and pharmacokinetic properties, making the complex structure manageable and systematically designable.
Solution Approach 2:
The patent employs the nested doll principle by incorporating a pyridine ring that is fused within the indole core structure. This nested arrangement integrates multiple functional features into a compact unified structure, where the pyridine nitrogen contributes to selectivity while sharing the structural space with the indole core, thereby reducing overall molecular complexity compared to having separate distinct units.
Data Source
AI summary
The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazole compounds are provided. The compounds are contemplated to be modulators of the 5-hydroxytryptamine 2A (5-HT2A) receptor.